News
-
-
PRESS RELEASE
MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
MIRA Pharmaceuticals advances Ketamir-2 into Phase 2a clinical evaluation for chemotherapy-induced peripheral neuropathy with potential for FDA Fast Track status -
-
PRESS RELEASE
Aclara To Build First Heavy Rare Earths Separation Facility in U.S. With a Secured Sustainable Ionic Clay Feed by Mid-2028
Aclara Resources Inc. announces the construction of the first heavy rare earths separation facility in the U.S., with Louisiana supporting the project. Key highlights include sustainable feed from Brazil and Chile, focus on advanced technologies -
-
-
-
PRESS RELEASE
EQS-Adhoc: Uniper SE: Uniper expects a significant decline in earnings for the nine months of the fiscal year 2025 in comparison to the previous year. Earnings outlook for fiscal year 2025 is confirmed
Uniper SE expects a significant decline in earnings for the nine months of fiscal year 2025 compared to the previous year, with confirmed outlook for the full year. Details on preliminary figures -
-
PRESS RELEASE
EQS-Adhoc: UBS AG: Changes to UBS’s Group Executive Board
UBS AG announces changes to its Group Executive Board, including new roles for key executives effective January 1, 2026. Michelle Bereaux to be Group Head Compliance and Operational Risk Control, Beatriz Martin as Group COO, and Mike Dargan focusing on technology advancement
